NDAORALTABLETPriority Review
Approved
Jan 2021
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VOCABRIA (cabotegravir sodium) is an oral integrase strand transfer inhibitor (INSTI) approved for HIV-1 treatment. It is a small molecule antiretroviral that blocks HIV integrase enzyme, preventing viral DNA integration into host cells. This drug represents a key component of GSK's HIV portfolio and can be used as part of combination antiretroviral therapy.
Peak4.4 years to LOE
Product is at peak commercial phase with moderate to high competitive intensity; brand teams are likely focused on market penetration and defending share against 8/10 competitive pressure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~5 years — strategic planning for patent cliff underway
Worked on VOCABRIA at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.